By David Winning

SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028.

Shares were recently up 8.3% at A$20.90 on Wednesday.

Neuren, a constituent of Australia's benchmark S&P/ASX 200 index, said more than 2,000 patients with Rett Syndrome have been treated with Daybue since its U.S. launch in 2023. That represents around a third of people in the U.S. with the disease.

Net sales of Daybue totaled US$101.1 million in the third quarter of last year.

In a recent presentation, Neuren's partner Acadia Pharmaceuticals said it has launched a new powder formulation known as Daybue Stix in the U.S. on a limited basis. That would come ahead of a full rollout by the beginning of April.

Acadia has projected this would help to drive sales growth toward the US$700 million target as Daybue Stix "could potentially enable patient growth from families who had declined to try or discontinued the liquid formulation," Neuren said in a regulatory filing on Wednesday.

Neuren's market value has risen to around 2.6 billion Australian dollars, equivalent to US$1.74 billion, on the back of demand for the Daybue treatment.

Neuren has a second drug candidate, known as NNZ-2591, in development as a treatment of several neurodevelopmental disorders. It has cited positive results from Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Write to David Winning at david.winning@wsj.com

(END) Dow Jones Newswires

January 13, 2026 19:23 ET (00:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.